Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints

Trial Identifier:	D6560R00004
Sponsor:	AstraZeneca
Collaborator:	RTI Health Solutions
NCTID::	NCT03290287
Start Date:	March 2017
Primary Completion Date:	June 2022
Study Completion Date:	June 2022
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United Kingdom	London, United Kingdom

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.